Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,672 SEK | +0.97% | +9.28% | +23.49% |
Sales 2024 * | 51.24B 559B 4,274B | Sales 2025 * | 54.8B 598B 4,570B | Capitalization | 236B 2,570B 19,652B |
---|---|---|---|---|---|
Net income 2024 * | 8.52B 92.91B 711B | Net income 2025 * | 10.2B 111B 850B | EV / Sales 2024 * | 4.99 x |
Net Debt 2024 * | 19.9B 217B 1,660B | Net Debt 2025 * | 13.44B 147B 1,121B | EV / Sales 2025 * | 4.55 x |
P/E ratio 2024 * |
28
x | P/E ratio 2025 * |
23.4
x | Employees | 89,900 |
Yield 2024 * |
2.04% | Yield 2025 * |
2.13% | Free-Float | 96.5% |
Latest transcript on AstraZeneca PLC
1 day | +0.97% | ||
1 week | +9.28% | ||
Current month | +15.08% | ||
1 month | +15.08% | ||
3 months | +18.88% | ||
6 months | +20.34% | ||
Current year | +23.49% |
Managers | Title | Age | Since |
---|---|---|---|
Pascal Soriot
CEO | Chief Executive Officer | 64 | 01/12/01 |
Aradhana Sarin
DFI | Director of Finance/CFO | 50 | 01/21/01 |
Cindy Hoots
CTO | Chief Tech/Sci/R&D Officer | 56 | 01/20/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Sherilyn McCoy
BRD | Director/Board Member | 65 | 01/17/01 |
Ahmed Hamdy
PRN | Corporate Officer/Principal | 59 | 01/13/01 |
Philip Broadley
BRD | Director/Board Member | 63 | 27/17/27 |
Date | Price | Change | Volume |
---|---|---|---|
30/24/30 | 1,672 | +0.97% | 124,463 |
29/24/29 | 1,656 | +0.58% | 292,246 |
26/24/26 | 1,646 | +0.27% | 316,442 |
25/24/25 | 1,642 | +6.35% | 917,143 |
24/24/24 | 1,544 | +1.41% | 341,079 |
Delayed Quote Nasdaq Stockholm, April 30, 2024 at 04:29 pm IST
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+33.25% | 704B | |
+28.59% | 577B | |
-3.55% | 348B | |
+18.16% | 327B | |
+4.36% | 288B | |
+4.93% | 198B | |
-9.78% | 194B | |
-3.69% | 147B | |
-5.59% | 145B |
- Stock Market
- Equities
- AZN Stock
- AZN Stock